Lana

Developing new drugs used to be ultra slow and hit or miss, but generative AI can quickly identify promising molecules and filter out the duds, enabling companies to get the best ones into testing in a fraction of the time.

No wonder Lilly's been investing big in the tech.

The firm partnered with NVIDIA last year to build AI infrastructure for running models on its own data.

What's good for Lilly could be good for everyone else.

AstraZeneca, Pfizer, and other big pharma players are also leaning hard into AI.

And they're increasingly looking to China for new drug pipelines, too.

Lower operating costs and a robust biotech ecosystem means that medicines there can move into development faster and cheaper.

At the same time, ready-made AI tools and platforms mean that smaller biotech firms can become plausible contenders much sooner.

Before we dive into the next story, it's time for our daily check-in with Carl.

You've got questions, he's got your answers.

Carl, what have you got for us?

Thanks, Carl.

Next up.

Europeans are expecting prices on just about everything to bubble up this year, from the cars they drive to the tea they drink.

Higher inflation seems to be brewing.

The European Commission's March survey showed that consumers are worried about a sticker shock coming, and they're probably not wrong.

At the same time, businesses said they're likely to raise prices.

Meanwhile, the European Central Bank, ECB, is trying to figure out whether the recent energy price increases will spill into the rest of the economy.

And this survey, at least, suggests they could.

Once people and businesses start expecting higher prices, they act differently.